Association of C/T Polymorphism in the LRP5 Gene with Circulating Follicle Stimulating Hormone in Caucasian Postmenopausal Women

I. ŽOFKOVÁ, M. HILL, K. ZAJÍČKOVA

Institute of Endocrinology, Prague, Czech Republic

Received April 26, 2006
Accepted October 3, 2006
On-line available November 6, 2006

Summary
The LRP5 gene is believed to be primarily associated with bone metabolism via Wnt signaling. The latter pathway, however, appears to control various other systems outside the skeleton. To find the relationships of the LRP5 gene to serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) in the cohort of normal postmenopausal women, we identified the C/T (c.4037:A1330V) polymorphism in the LRP5 gene using a restriction analysis of the PCR product in a cohort of 165 untreated pre- and post-menopausal women. In a subset of 111 post-menopausal women we analyzed the association between the LRP5 genotype and serum levels of sex-hormones including FSH and LH. The distribution of CC, TC and TT genotypes of the C/T polymorphism in the whole group was 73.9 %, 23.6 % and 2.4 %, respectively, which is comparable with other Caucasian populations. As no TT homozygote was found in the group of post-menopausal women, serum sex-hormones were compared between CC and TC genotypes. Women with the CT allele combination had markedly higher serum FSH levels as compared to carriers of the CC genotype (p<0.004). No differences between these genotypes were found in serum LH levels as well as the circulating sex-steroids such as estradiol, testosterone, dehydroepiandrosterone and/or its sulphate, androstenedione and SHBG. To conclude, the LRP5 gene is associated with circulating FSH in normal post-menopausal women in the present study. The mediating role of subtle undetectable variations in estrogen levels is discussed. We did not find any relationship between the LRP-5 genotype and serum LH levels.

Key words
Follicle stimulating hormone • Luteinizing hormone • Sex-steroids • LRP5 gene • C/T (c.4037:A1330V) polymorphism

Introduction
The low-density lipoprotein receptor-related protein 5 (LRP5) gene on chromosome 11q13 plays a key role in the Wnt canonical pathways, which act as various ligands to stimulate signal transduction (Johnson et al. 2004). It is known that LRP5 is essential for normal morphology, development processes, mechnano-sensation and formation of bone (Li et al. 2005). The LRP5 gene contributes to normal variations in peak bone mass (Koller et al. 2005) and is associated with the risk of osteoporosis and fractures in elderly women (Bollerslev et al. 2005).
However, LRP5 is a widely expressed receptor maintaining physiological homeostasis of various other systems. Its central role in binding, endocytosis and degradation of cholesterol-rich lipoproteins is well known (North et al. 2000, Johnson et al. 2004). The LRP5 gene is hypothesized to be a candidate gene for type-1 diabetes (Twells et al. 2003). Furthermore, LRP5 has been implicated in the pathogenesis of some degenerative processes such as malignant diseases (Kuhnen et al. 2000). Associations between candidate genes for osteoporosis and serum sex-hormone levels have been observed in post-menopausal women. This is understood in the context of the common evolution of bone and reproduction (Žofková et al. 2002a,b,c, 2004). Moreover, Wnt is believed to be one of extrinsic signals arising from the ventral diencephalon and regulating early pituitary development (Asa and Ezzat 2004). The aim of the present study was to analyze the relationship between the additional candidate gene for bone metabolism - the LRP5 and serum sex-hormones in normal post-menopausal women.

Methods

Subjects

Genotyping was carried out in 165 untreated pre- and post-menopausal Caucasian women. Further analysis of serum gonadotropins, sex-steroids and bone density was performed in a subset of 111 postmenopausal women (mean age 62.8±9.4 years, 13.4±7.5 years since menopause).

None of the investigated women had a history of early or late menarche or premature menopause (before 45 years of age). Women with unclear menopausal status were not included in the study. The prior menstrual history of subjects was regular (11-13 cycles/year). The study group did not include any alcoholics, severe smokers, women with psychosis, endocrinopathies or other serious internal diseases. All women gave their informed consent prior to their inclusion in the study. All procedures have been reviewed by the Ethics Committee of the Institute of Endocrinology in Prague.

Protocol

Blood for measurement of serum follicle stimulating hormone (FSH), luteinizing hormone (LH), sex-steroids and sex hormone binding globulin (SHBG) levels was collected in the morning after overnight fasting. Samples were stored at –80 °C until analyzed.

Analytical methods

Serum concentrations of FSH (normal postmenopausal range 27-129 U/l) and LH (normal postmenopausal values >12 U/l) were determined by commercial IRMA kits from Immunotech (France) using the Startec analyzer (France) and a monoclonal antibody against biologically and immunologically specific beta sub-unit.

Serum androstenedione was determined using the method described by Putz et al. (1982), unconjugated dehydroepiandrosterone (DHEA) and its sulphate were measured by commercial kits from Immunotech (France). Serum total testosterone levels were estimated by the modified method using [125I] tyrosyl methyl ester as a tracer. Serum estradiol was estimated using a commercial kit from Immunotech (France). Duplicate measurements were used to calculate mean values. The inter-assay coefficients of variation were as follows: 6.5 % for FSH, 7.5 % for LH, 11.4 % for androstenedione, 11.9 % for DHEA, 10.6 % for DHEA sulphate, 10 % for testosterone and 15 % for estradiol.

Genotyping of LRP5

The C/T (c.4037:A1330V) polymorphism of the LRP5 gene was determined by a restriction analysis of the PCR product as described by Okubo et al. (2002). A mismatched forward primer (GAC TGT CAG GAC CGC TCA CAC G) introduces a restriction site for DraIII enzyme. We shifted a reverse primer forward to produce a large PCR product for further restriction (AAG GTT TTC AGA GCC CCT AC) (GenBank, accession No. NT 033903). A PCR product of 230 bp was digested with Adel (Fermentas, Lithuania), an isoschizomere of DraIII, at 37 °C overnight. After cleavage, the fragments were separated on a 3 % agarose gel. The presence of the Adel restriction site yielded fragments of 206 and 24 bp.

Statistical analysis

Data are presented as means ± S.D. After adjustment for the years since menopause, analysis of covariance (ANCOVA) was used to compare quantitative data within the genotypes. Due to non-symmetric data distribution in most of the variables, the original values were transformed by a power transformation to maximum concordance with the Gaussian distribution. In addition, the dependent variables were corrected to symmetric
2007

LRP5 Genotype and Serum FSH 737

distribution and homoscedasticity of residuals in
ANCOVA model. Statistics were performed using the
Statgraphics plus v.5.1 software from Manugistics
(Rockville, USA).

Results

The allele frequencies of the C/T (LRP5, c.4037:
A1330V) polymorphism in our population were as
follows: CC 73.9 %, TC 23.6 % and TT 2.4 %, which
reached the Hardy-Weinberg equilibrium (χ²=0.1959,
p≥0.90) and did not differ from other Caucasian
populations (Koller et al. 2005, Bollerslev et al. 2005).
No TT homozygote was found within the group of 111
post-menopausal women investigated for sex-hormone
levels. Thus the data were compared between the CC and
TC genotypes. Higher levels of FSH were observed in
women with the CT genotype compared to CC
homozygotes (p<0.004). Besides adjustment to constant
YSM (Table 1), the additional covariate serum estradiol
was inserted into the model. In this case, a significant
effect of the LRP-5 genotype on serum FSH was
confirmed (p<0.006). Finally, unadjusted ANCOVA
showed an even higher significance of this relationship.
Furthermore, a 9.6 % variation in FSH levels may be
explained by the LRP5 genotype. No differences between
these genotypes were found in serum LH, sex steroids
and their precursors and SHBG (Table 1).

Discussion

In the present study we showed a strong
association between serum FSH levels and C/T
polymorphism in the LRP5 gene in untreated post-
menopausal women. On the other hand, we found no
relationship between the genotype and circulating LH,
estradiol, testosterone and/or their precursors.

Physiological production of gonadotropins is
primarily encoded by different genes located on
chromosomes 6, 11 and 19 (Malmed and Kleinberg
2003). As to FSH, a critical role is played by the FSH -
beta subunit gene with the AluI element (Du et al. 2002,
Hirst et al. 2004). Furthermore, association of serum
gonadotropin levels with the calcium-sensing receptor
(CaR) gene (intron 5C/T polymorphism) has been shown
in postmenopausal women (Žofková et al. 2005).

Wnts are secreted glycoproteins that bind to
receptor complexes including LRP5. A subsequent
intracellular cascade of events stabilizes beta-catenin,
leading to its translocation into the nucleus, where
associated with Tcf/Lef transcription factors, it triggers
gene expression in target cells (Riwadi and Roman-
Roman 2005). Although there are no data documenting
expression of LRP5 receptors directly in pituitary tissue,
the receptor is to a lower extent expressed in the brain
(Koay and Brown 2005). This does not exclude the direct
association between the LRP5 gene and FSH synthesis.
Circulating FSH is a well-known supersensitive indicator

<table>
<thead>
<tr>
<th>Variable</th>
<th>GENOTYPE</th>
<th>ANCOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CC</td>
<td>CT</td>
</tr>
<tr>
<td></td>
<td>n  Mean</td>
<td>S.D.</td>
</tr>
<tr>
<td>Age (years)</td>
<td>84 62.8</td>
<td>9.4</td>
</tr>
<tr>
<td>YSM (years)</td>
<td>84 13.4</td>
<td>8.6</td>
</tr>
<tr>
<td>E2 (nmol·l⁻¹)</td>
<td>84 0.088</td>
<td>0.108</td>
</tr>
<tr>
<td>T (nmol·l⁻¹)</td>
<td>83 1.49</td>
<td>0.72</td>
</tr>
<tr>
<td>DHEAS (nmol·l⁻¹)</td>
<td>84 1.49</td>
<td>1.47</td>
</tr>
<tr>
<td>DHEA (nmol·l⁻¹)</td>
<td>82 2.35</td>
<td>1.45</td>
</tr>
<tr>
<td>A-dione (nmol·l⁻¹)</td>
<td>83 3.14</td>
<td>2.35</td>
</tr>
<tr>
<td>SHBG (nmol·l⁻¹)</td>
<td>84 29.6</td>
<td>61.1</td>
</tr>
<tr>
<td>FSH (U·l⁻¹)</td>
<td>81 33.0</td>
<td>29.0</td>
</tr>
<tr>
<td>LH (U·l⁻¹)</td>
<td>82 12.9</td>
<td>20.0</td>
</tr>
</tbody>
</table>

YSM-adjusted ANCOVA was used to evaluate the differences between CC and CT genotypes. YSM – years since menopause.

Table 1: Hormonal and anthropometrical characteristics of postmenopausal women.
of sex-steroid homeostasis. Thus, the effect mediated by the primary association between LR5P and estrogen synthesis cannot be excluded, similarly to the effect of ovarian inhibin A and inhibin B, the disappearance of which is an important predictor of approaching menopause (Overli et al. 2005).

Failure to find an association between the LR5P gene and serum LH levels is explained by the fact that both these gonadotropic systems are mutually independent. Additionally, LH production appears to be controlled separately by specific polymorphisms, such as Trp8Arg, Ile15Thr and Gly102Ser in the LH beta-subunit gene (Lee et al. 2003).

Except for the C/T polymorphism, several other polymorphisms, such as Q89R, N740N and A1330V have been identified in the LR5P gene (Zhang et al. 2005). Unfortunately, relationships of circulating sex-hormones to these polymorphisms have not been investigated yet.

In conclusion, circulating FSH has been associated with the LR5P gene in the present study. This finding strengthens the hypothesis that LR5P is an important pleiotropic mechanism involved in ageing and menopause (Ferrari and Rizzoli 2005). Moreover, it supports the concept of the common evolution of calcium regulating and reproduction systems.

Acknowledgements
The study was funded by the IGA grant NR/7827-3 from the Ministry of Health of the Czech Republic.

References


**Corresponding author**
I. Žofková, Institute of Endocrinology, Prague, Czech Republic. E-mail: izofko@endo.cz